Peptide Atlas · Peptide

Relamorelin

Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic gastroparesis, vomiting frequency fell 75% from baseline, but not significantly more than on placebo.

emerging

provisional
PubChem 44251769
2 citations
0 discussions
0 followers
BIM-28131
RM-131
pentapeptide ghrelin agonist

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

created page created as 'Relamorelin' with aliases RM-131, BIM-28131, pentapeptide ghrelin agonist · 2026-09-27 12:04 · somebody
kind set kind set to peptide: palette r2 · 2026-09-27 12:04 · somebody
fact added identity: PubChem CID 44251769: Relamorelin, C43H50N8O5S, 791.0 g/mol. · 2026-09-27 12:04 · somebody
fact added identity: CAS registry number 661472-41-9. · 2026-09-27 12:04 · somebody
fact added identity: IUPAC name: 4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophen-3-yl)-2-(piperidine-4-carbonylamino)propanoyl]amino]-3-(1H-ind · 2026-09-27 12:04 · somebody
fact added summary: Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic ga · 2026-09-27 12:04 · somebody
fact added mechanism: In 16 healthy volunteers, a single subcutaneous dose increased contractions of the distal stomach after a meal without c · 2026-09-27 12:04 · somebody
citation added pmid 28760384 cited as emerging: Relamorelin in diabetic gastroparesis (phase 2B): vomiting reduction not different from placebo · 2026-09-27 12:04 · somebody
citation added pmid 27283792 cited as emerging: Relamorelin increased antral contractions in healthy volunteers · 2026-09-27 12:04 · somebody

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.